Renovis Ends Phase Ia Clinical Trial with REN-850
Monday June 13, 8:00 am ET
SOUTH SAN FRANCISCO, Calif., June 13 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News) announced today that it has ended its Phase Ia clinical trial for REN-850, an investigational small molecule that was being studied for the treatment of multiple sclerosis (MS). The objective of this study was to assess the safety, tolerability and pharmacokinetics of escalating single doses of REN-850 in healthy volunteers. Based on preclinical studies REN-850 is believed to act by inhibition of leukocyte trafficking.
"Interim data from the Phase Ia study with REN-850 revealed unexpected pharmacokinetic properties that were not predicted by preclinical testing of the drug candidate. After careful consideration of these data we have decided to end further development of REN-850," said Randall Moreadith, M.D., Ph.D., Chief Medical Officer of Renovis.
About Renovis
Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. Our most advanced product candidate, CEROVIVE® (NXY-059), is in Phase III clinical trials for acute ischemic stroke with our exclusive licensee, AstraZeneca AB. CEROVIVE (NXY-059), an investigational drug under development by AstraZeneca and licensed from Renovis, has a proposed mechanism of action of free radical trapping. It is being studied as a neuroprotectant in clinical trials based on effects seen in experimental models of acute ischemic stroke. We are independently developing REN-1654, an oral drug candidate for neuropathic pain in a Phase II clinical trial for sciatica. Our research and development programs focus on major medical needs in the areas of neuroprotection, pain and neuroinflammatory diseases. We have a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule VR1 antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury.
For additional information about the company, please visit renovis.com.
CEROVIVE (NXY-059) is a registered trademark of the AstraZeneca group of companies. All other product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners. |
